Compare Amphastar Pharmaceuticals Inc (AMPH) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs AngloGold Ashanti Limited — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while AngloGold Ashanti Limited trades at $97 (market cap $49.19B). The key difference: AngloGold Ashanti Limited is far larger — about 56.9× Amphastar Pharmaceuticals Inc's market cap, and AngloGold Ashanti Limited pays a 4.65% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | AU | |
|---|---|---|
Market Cap | $863.95M | $49.19B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $128.26 |
52-Week Low | $16.87 | $52.15 |
Enterprise Value | $1.26B | $48.20B |
Dividend Yield | — | 4.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
AngloGold Ashanti (AU) surged 9.85% to $96.22 on strong gold price momentum and positive Q2 earnings. The stock trades near its 52-week high with bullish technical indicators and robust fundamentals including 26.64% net margins and 46.5% ROE. Recent quarterly results showed mixed performance with Q1 beating expectations while Q2 slightly missed, but strong free cash flow growth supports increased shareholder returns including dividends and a $2 billion buyback program.
Outlook remains positive with analyst consensus at $120.33 target (25% upside) and 64% buy ratings. Key catalysts include H2 production growth and gold price strength, while risks involve operational disruptions and commodity volatility. The company's improving balance sheet and cash generation support continued dividend payments and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
